Company Overview

Know Labs is an emerging developer of non-invasive medical diagnostics, focused on bringing the world's first FDA-cleared non-invasive blood glucose monitor to the marketplace. 

Latest Company Presentation

American Diabetes Association’s 84th Scientific Sessions (ADA 2024)

Latest Financial Results

Q3 2024

Quarter Ended June 30, 2024

Earnings Release

Earnings Webcast

10-Q

XBRL

Company Information

Know Labs, Inc. is a developer of non-invasive medical diagnostics technology that uses radiofrequency dielectric spectroscopy to identify and measure a wide range of organic and inorganic materials, molecules, and compositions of matter. The technology can be integrated into a variety of wearable, mobile, or bench-top form factors.

Nearly two billion people around the world suffer from diabetes and prediabetes. The Company's first focus is a non-invasive continuous glucose monitoring device that will provide the user with highly accurate, real-time information on their blood glucose levels, assisting people with diabetes and prediabetes to manage these medical conditions.

As the leading worldwide IP holder in non-invasive blood glucose monitoring with more than 270 patents issued, pending and in process, Know Labs has created a defensible moat surrounding its technology.

Clinical testing is expanding as the Company continues to refine the KnowU, wearable non-invasive CGM and trade-secret algorithms on its path toward FDA clearance. Once FDA clearance is secured, the Company will become the world's first FDA-cleared non-invasive glucose monitor in a $21B+ global market.

IR Contacts

Corporate Office

Know Labs, Inc.
619 Western Ave
Suite 610
Seattle, WA 98104
United States

Investor Relations

Pete Conley
CFO & SVP of IP
T: 310-383-7874
pete@knowlabs.co

Transfer Agent

Equiniti Trust Company, LLC
55 Challenger Road, Floor 2
Ridgefield Park, NJ 07660
United States

Connect With Us